

The syntheses and crystal structure of novel 5-methyl-3-substituted-1,2,4-triazolo[3,4-b]benzothiazoles

Heng-Shan Dong^{a,*}, Bin Quan^b, Er-Feng Chai^b, Xue-Rong Mao^b

^aNational Laboratory of Applied Organic Chemistry, Institute of Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, People's Republic of China

^bDepartment of Chemistry, Guansu Education College, Lanzhou, Gansu 730000, People's Republic of China

Received 1 March 2001; revised 23 October 2001; accepted 23 October 2001

Abstract

Novel 5-methyl-3-substituted-1,2,4-triazolo[3,4-b]benzothiazoles were synthesized from *o*-methylaniline to **5** with various aromatic carbonic acids. The yielded product **6a–e** were confirmed by Elemental Analyses, NMR, MS, IR spectra and **6e** was investigated with X-ray crystallography. Compound **6e**, C₂₄H₁₆N₄S, Mr = 392.69, crystallized in the triclinic space group *P* $\bar{1}$ with unit cell parameters *a* = 9.713(3) Å, *b* = 14.645(4) Å, *c* = 15.641(3) Å, α = 113.17(2)°, β = 90.11(2)°, γ = 109.29(2)°, *V* = 1908.1(7) Å³, *Z* = 4, *D*_m = 1.366 Mgm^{−3}. © 2002 Elsevier Science B.V. All rights reserved.


Keywords: Tricyclazole derivative; Synthesis; 1,2,4-Triazolo[3,4-b]benzothiazole; Crystal structure

1. Introduction

Tricyclazole is one of the benzothiazole derivatives, which are well known for developing this synthesis of many compounds with this ring system beading diverse biological activities such as application as potent antibacterials [1,2] and fungicides for the control of *Piricularia oryzae* in the prevention of rice blast [3]. The crystal structure of this heterocyclic system was not found in literature up to now. In recent years, fused heterocycles have been found to possess many unique properties in synthesis and pharmacology. In particular, *s*-triazolo[3,4-b]benzothiazole derivatives are of interest because of their broad spectra of biological activities. The structure, which is established, should be yearned for studying relation between definite structure and properties in these fields. It should be referenced that studies of analo-

gous compounds are promoted. We have reported the crystalline structure of 2-(3-bromoanilino)-5-[5-amino-1-(4-chlorophenyl)-1,2,3-triazol-4-yl]-1,3,4-thiadiazole and their derivatives [4–7]. We have obtained the crystalline structure of a new compound 3-[5-methyl-1-(4-methylphenyl)-1,2,3-triazol-4-yl]-6-(4-methylphenyl)-*s*-triazolo[3,4-b]-1,3,4-thiadiazole. Therefore, it was planned to investigate a system, which combines these three biologic components in a ring to give a compact system for screening their biologic activities. Recently, we have synthesized several novel 5-methyl-3-substituted-1,2,4-triazolo[3,4-b]benzothiazoles from *o*-methylaniline to **5** with various aromatic carbonic acids. The yielded products **6a–e** were investigated with Elemental Analyses, NMR, MS, IR techniques and **6e** was investigated with X-ray crystallography. Compound **6e**, C₂₄H₁₆N₄S, Mr = 392.69, crystallized in the triclinic space group *P* $\bar{1}$ with unit cell parameters *a* = 9.713(3) Å, *b* = 14.645(4) Å, *c* = 15.641(3) Å,

* Corresponding author. Tel.: +86-931-891-582.



Scheme 1.

$\alpha = 113.17(2)^\circ$, $\beta = 90.11(2)^\circ$, $\gamma = 109.29(2)^\circ$,
 $V = 1908.1(7) \text{ \AA}^3$, $Z = 4$, $D_m = 1.366 \text{ Mg m}^{-3}$.

The synthesis pathway of compound **6** is shown in Scheme 1 (the syntheses route of compounds **6a–e**).

2. Results and discussion

The structure of the title compound is shown in Fig. 1. The unit cell parameters of the title compound is shown in Fig. 2. In recent years the synthesis and characteristics of *s*-triazolo[3,4-*b*]1,3,4-thiadiazoles [8,9] and 7*H*-*s*-triazolo[3,4-*b*]-1,3,4-thiadiazine derivatives [10] have been investigated. These heterocyclic compounds contain 1,2,4-triazole and benzothiazole rings condensed through a C–N bond. The substituted groups at the 3 positions cannot conjugate with the heterocyclic nucleus giving it new characteristics in a continuation of our earlier studies [4]. We report the syntheses of several novel 5-methyl-3-

substituted-1,2,4-triazolo[3,4-*b*]benzothiazoles **6a–e** show in Table 1.

The spectral data of **6a–e** presented in Tables 2–4. IR absorption peaks of **5** at 3167, 3203 cm^{-1} are assigned to its NHNH_2 group. When **5** is converted **6**, the NHNH_2 perk disappears but a new peak characteristic of $\nu_{\text{C=N}}$ appears at 1588–1626 cm^{-1} . Like the allied system [4]. The $\nu_{\text{C-S-C}}$ absorption peaks of compound **6a–e** are in the region of 693–702 cm^{-1} .

In ^1H NMR spectra, compared **5** and **6a–e**, we found that after cyclization the evident change is that the signals of $-\text{NHNH}_2$ protons are at δ 3.11 ppm. The chemical shifts of the aromatic methyl group show in the range of δ 2.36–2.52 ppm. The chemical shifts of the triazole methyl group show in the range δ 2.33–2.75 ppm, and the chemical shift of the aromatic ring methyl group on the 1,2,4-triazolo[3,4-*b*]benzothiazole ring in compound **6e** occurs at higher frequency than the other compounds.

Single crystals were selected and were mounted on




Fig. 1. ORTEP drawing of the title compound showing the atom numbering scheme.




Fig. 2. The unit cell parameters of the title compound.

Table 1

Structures, yields and melting points of the compounds **6a–e** (Ar = **6a** 5-methyl-1-(4-chlorophenyl)-1,2,3-triazol-4-yl; **6b** 5-methyl-1-(4-methylphenyl)-1,2,3-triazol-4-yl; **6c** 5-methyl-1-(2-methylphenyl)-1,2,3-triazol-4-yl; **6d** 2,4-dichlorophoxymethylene; **6e** 2-phenylquinoline-4-yl)

| Compound | Yield (%) | Mp (°C) | Formula | Found (required) (%) | | |
|-----------|-----------|---------|---|----------------------|------------|--------------|
| | | | | C | H | N |
| 6a | 42 | 252–253 | C ₁₈ H ₁₃ ClN ₆ S | 56.68(56.77) | 3.40(3.44) | 22.27(22.07) |
| 6b | 60 | 220–221 | C ₁₉ H ₁₆ N ₆ S | 63.27(63.31) | 4.42(4.47) | 23.43(23.32) |
| 6c | 67 | 143–144 | C ₁₉ H ₁₆ N ₆ S | 63.23(63.31) | 4.46(4.47) | 23.45(23.32) |
| 6d | 57 | 125–126 | C ₁₆ H ₁₁ Cl ₂ N ₃ OS | 52.68(52.76) | 3.10(3.04) | 11.62(11.54) |
| 6e | 45 | 228–229 | C ₂₄ H ₁₆ N ₄ S | 73.39(73.45) | 4.08(4.11) | 14.38(14.28) |

the tip of a glass fiber. Preliminary examination and data collection were performed with Mo K α radiation ($\lambda = 0.71073$ Å) on an Enraf–Nonius CAD4 computer controlled kappa axis diffractometer operating in the $\omega/2\theta$ scanning mode using the crystal. The structure was determined by direct methods (SHELXS-86) and refined by full covariance matrix methods (SHELXL-93). The crystal data and the refinement detail gives in Table 5.

The structure of the title compound is shown in Fig. 1. The fractional coordinates and mean temperature factors with estimated standard deviations for non-hydrogen atoms are listed in Table 6 and selected bond lengths are given in Table 7, selected bond angles are given in Table 8. The geometric calculations were performed using the program SHELXS-86.

The central ring system in the present compound is already determined. The bond lengths indicate a degree of delocalization around the ring system with

the three C=N bonds ranging from 1.294(4) to 1.306(4) Å and the N–N bond lengths ranging 1.392(4) Å. The benzothiazole ring system is planar. The bond lengths N2–C8 1.373(4) Å, N2–C7 1.422(4) Å, S1–C6 1.756(4) Å, S1–C8 1.719(3) Å are not in agreement with the values reported for benzothiazole by Fehlmann [11] (the bond lengths N2–C8 1.297 Å, N2–C7 1.381 Å, S1–C6 1.739 Å, S1–C8 1.763 Å). The bond lengths N2–C8 1.297 Å [11] and N2–C8 1.373(4) Å are between the bond lengths of C=N and C–N. The structure of the title

Table 3

¹H NMR spectral data for compounds **6a–e** (Bti: benzothiazole; Tazo: 1,2,3-triazol)

| Compound | ¹ H NMR (CDCl ₃ – d), δ (ppm), J (Hz) |
|-----------|--|
| 6a | 7.14–7.72 (m, 3H, Bti-H), 7.14–7.47 (q or 2d, 4H, $J = 8.5$, p -ClC ₆ H ₄ –), 2.45 (s, 3H, Bti-CH ₃), 2.75 (s, 3H, Tazo-CH ₃) |
| 6b | 7.13–7.60 (m, 3H, Bti-H), 7.42 (s, 4H, 4-CH ₃ C ₆ H ₄), 2.49 (s, 6H, Bti-CH ₃ , Tazo-CH ₃), 2.10 (s, 3H, 4-CH ₃ C ₆ H ₄) |
| 6c | 7.15–7.63 (m, 7H, Bti-H, 2-CH ₃ C ₆ H ₄), 2.33 (s, 3H, Tazo-CH ₃), 2.33 (s, 3H, Bti-CH ₃), 2.14 (s, 3H, 2-CH ₃ C ₆ H ₄) |
| 6d | 6.93–7.60 (m, 6H, –C ₆ H ₃ Cl ₂ , Bti-4H), 4.97 (s, 2H, –OCH ₂ –), 2.58 (s, 3H, Bti-CH ₃) |
| 6e | 8.35–8.33 (d, 1H, $J = 8.3$, 8'-H), 8.25–8.26 (m, 1H, $J = 1.5$, Bti-8H), 8.23 (s, 1H, 5'-H), 8.22 (s, 1H, 7'-H), 7.79–7.83 (m, 1H, $J = 8.2$, $J = 1.52$, Bti-7H), 7.48–7.58 (m, 5H, Ph-H), 7.31 (s, 1H, 3'-H), 7.26–7.27 (d, 1H, $J = 1.48$, Bti-6H), 6.99–7.01 (d, 1H, $J = 7.63$, 6'-H), 1.51 (s, 3H, Bti-5CH ₃) |

Table 2

IR spectral data for compounds **6a–e**

| Compound | IR(cm ⁻¹) (KBr disc) |
|-----------|--|
| 6a | 3067, 3014, 2919, 2851, 1679, 1551, 1498, 1426, 1369, 1258, 980, 861, 823, 723.5 |
| 6b | 3067, 2969, 2922, 2864, 1650, 1558, 1518, 1483, 1383, 971, 862, 798, 722.4 |
| 6c | 3077, 2968, 2930, 2864, 1612, 1501, 1481, 1407, 1382, 1259, 971, 861, 807, 722.1 |
| 6d | 3191, 2918, 1615, 1556, 1480, 1454, 1362, 1291, 1231, 1122, 984, 860, 815, 720.9 |
| 6e | 3057, 2974, 2917, 1600, 1548, 1481, 1445, 1355, 1240, 956.9, 824, 762, 721.1 |

Table 4
MS spectral data for compounds **6a–e**

| No | M ⁺ | m/z (%) |
|-----------|----------------|--|
| 6a | 381(25) | 353(6), 326(5), 320(8), 300(1), 292(9), 285(2), 229(4), 285(2), 229(4), 194(6), 191(29), 181(11), 175(15), 163(20), 154(23), 153(32), 152(62), 149(34), 146(10), 139(5), 136(23), 128(15), 123(10), 121(22), 119(6), 113(33), 111(100), 109(19), 102(16), 101(11), 92(13), 91(7), 77(23), 75(59), 51(13) |
| 6b | 360(22) | 345(54), 332(17), 331(22), 318(22), 317(100), 303(9), 290(10), 289(14), 274(2), 263(4), 247(2), 214(2), 200(7), 197(4), 190(2), 184(3), 171(5), 170(29), 169(49), 163(22), 162(16), 156(19), 155(11), 143(31), 136(18), 132(34), 128(13), 122(11), 121(14), 119(9), 102(10), 91(75), 77(19), 65(50) |
| 6c | 360(17) | 345(49), 332(12), 331(16), 318(22), 317(100), 303(8), 290(8), 289(13), 276(2), 274(2), 263(3), 256(2), 247(2), 214(2), 200(7), 197(4), 190(1), 184(2), 171(4), 170(25), 169(48), 163(23), 162(21), 156(15), 143(27), 136(18), 132(22), 128(15), 121(17), 117(13), 109(10), 102(12), 91(80), 89(23), 77(25), 65(77) |
| 6d | 363(4) | 328(1), 240(17), 239(6), 238(47), 223(1), 203(15), 202(100), 184(2), 177(27), 173(8), 163(9), 161(26), 150(12), 148(8), 136(8), 133(7), 121(7), 117(13), 109(8), 103(3), 92(5), 77(6), 65(5) |
| 6e | 392(70) | 378(27), 377(100), 364(10), 359(1), 334(1), 317(2), 315(24), 289(3), 256(2), 231(17), 230(73), 229(98), 204(9), 203(10), 196(16), 189(1), 176(6), 175(5), 162(53), 161(55), 151(14), 147(9), 136(15), 135(27), 126(5), 122(7), 121(12), 118(24), 110(12), 109(12), 92(17), 91(13), 77(20), 65(12) |

Table 5
Crystal data and summary of data collection and structure refinement

| | |
|---|---|
| Compound | C ₂₄ H ₁₆ N ₄ S |
| Color/Shape | Colorless/rhombic pillared |
| Formula weight | 392.47 |
| Temperature (°C) | 20 (293 K) |
| Crystal system | Triclinic |
| Space group | <i>P</i> $\bar{1}$ |
| Cell constants | |
| <i>a</i> (Å) | 9.713(3) |
| <i>b</i> (Å) | 14.645(4) |
| <i>c</i> (Å) | 15.641(8) |
| α (°) | 113.17(2) |
| β (°) | 90.11(2) |
| γ (°) | 109.29(2) |
| Volume (Å ³) | 1908.1(7) |
| Formula units/unit cell | 4 |
| <i>D</i> _{calc} (g cm ^{−3}) | 1.366 |
| <i>F</i> (000) | 816 |
| Absorption coefficient (mμ ^{−1}) | 0.188 |
| Diffractionmeter/scan Enraf–Nonius CAD4 | $\omega/2\theta$ |
| Radiation, graphite monochromator Mo K α | 0.71073 |
| Reflections for cell measurement and θ range (°) | 25, 0 ~ 25 |
| Index ranges | 0 ≤ <i>h</i> ≤ 11; −17 ≤ <i>k</i> ≤ 16; −18 ≤ <i>l</i> ≤ 18 |
| Standard reflections | 7149 |
| Reflections measured | 6714 |
| Reflection observed [<i>I</i> > 2σ(<i>I</i>)] | 4237 (<i>R</i> _{int} = 0.0322) |
| Maximum value of θ (°) | 25.02 |
| Computing | Data collection CAD4 Cell refinement CAD4 Data reduction PCSDP Structure solution SHELXS-86 SHELXL-93 |
| Structure refinement | 6649/0/523 |
| Data/restraints/parameters | 1.134 |
| Goodness-of-fit on <i>F</i> ² | <i>R</i> ₁ = 0.0514, <i>wR</i> ₂ = 0.1364 |
| Final <i>R</i> indices | 0.369 and −0.391 eÅ ^{−3} |
| Largest diff. peak and hole | |

compound is shown in Scheme 2 (the structure of 5-methyl-3-(2-phenylquinoline-4-yl)-1,2,4-triazolo [3,4-*b*]benzothiazole **6e**).

3. Experimental

Melting points were determined on a Kofler melting point apparatus and are uncorrected. The mass spectrum was performed on a HP-5988A

Table 6

The fractional coordinates and mean temperature factors with estimated standard deviations for non-hydrogen atoms

| | X | Y | Z | U |
|-----|-------------|------------|------------|------------|
| S1 | 0.31523(10) | 0.60184(7) | 0.95148(7) | 0.0647(3) |
| N1 | 0.5804(3) | 0.5688(2) | 0.9294(2) | 0.0616(7) |
| N2 | 0.3749(3) | 0.4377(2) | 0.8413(2) | 0.0462(6) |
| N3 | 0.6140(3) | 0.4810(2) | 0.8721(2) | 0.0609(7) |
| N4 | 0.5497(3) | 0.1107(2) | 0.6564(2) | 0.0552(7) |
| C1 | 0.1623(4) | 0.2240(3) | 0.6770(3) | 0.0734(11) |
| C2 | 0.1218(4) | 0.3130(3) | 0.7449(3) | 0.0610(9) |
| C3 | −0.0241(4) | 0.3061(4) | 0.7380(3) | 0.0830(12) |
| C4 | −0.0689(5) | 0.3864(4) | 0.7954(4) | 0.0954(15) |
| C5 | 0.0269(4) | 0.4779(4) | 0.8634(3) | 0.0834(12) |
| C6 | 0.1737(4) | 0.4871(3) | 0.8719(3) | 0.0609(9) |
| C7 | 0.2203(3) | 0.4060(3) | 0.8157(2) | 0.0518(7) |
| C8 | 0.4389(3) | 0.5398(2) | 0.9094(2) | 0.0539(8) |
| C9 | 0.4931(3) | 0.4034(2) | 0.8212(2) | 0.0486(7) |
| C10 | 0.4974(3) | 0.2982(2) | 0.7604(2) | 0.0490(7) |
| C11 | 0.4486(3) | 0.2124(2) | 0.7881(2) | 0.0512(7) |
| C12 | 0.3757(4) | 0.2149(3) | 0.8660(3) | 0.0604(8) |
| C13 | 0.3333(5) | 0.1294(3) | 0.8880(3) | 0.0780(11) |
| C14 | 0.3634(5) | 0.0381(3) | 0.8331(3) | 0.0836(12) |
| C15 | 0.4341(4) | 0.0332(3) | 0.7581(3) | 0.0708(10) |
| C16 | 0.4785(3) | 0.1197(3) | 0.7324(2) | 0.0540(8) |
| C17 | 0.5662(3) | 0.2869(3) | 0.6829(2) | 0.0506(7) |
| C18 | 0.5912(3) | 0.1911(2) | 0.6315(2) | 0.0483(7) |
| C19 | 0.6750(3) | 0.1808(3) | 0.5511(2) | 0.0537(8) |
| C20 | 0.7266(4) | 0.0974(3) | 0.5146(3) | 0.0697(10) |
| C21 | 0.8168(5) | 0.0927(4) | 0.4463(3) | 0.0855(13) |
| C22 | 0.8540(5) | 0.1685(4) | 0.4115(3) | 0.0875(13) |
| C23 | 0.7991(5) | 0.2492(4) | 0.4444(3) | 0.0813(11) |
| C24 | 0.7105(4) | 0.2552(3) | 0.5133(3) | 0.0666(9) |

spectrometer (EI at 70 eV). IR spectra were obtained in KBr discs using a Nicolet 170SX FT-IR spectrometer. ^1H NMR spectroscopy were recorded at room temperature at 400.13 MHz on a Bruker AM 400 instrument. Elemental Analyses were carried out on a Yanaco CHN Corder MT-3 analyzer.

Phosphorus oxychloride was redistilled (bp 105 °C).

5-Methyl-1-(4-methylphenyl)-1,2,3-triazol-4-carboxylic acid, 5-Methyl-1-(2-methylphenyl)-1,2,3-triazol-4-carboxylic acid and 5-Methyl-1-(4-cholophenyl)-1,2,3-triazol-4-carboxylic acid were prepared by the literature [9].

3.1. The preparation of the *o*-tolylthiourea 3

A mixture of *o*-toluidine (25.4 g, 0.24 mol) and

chlorobenzene (130 ml) was heated. After *o*-toluidine was dissolved, concentrated hydrochloride (21 ml, 0.25 mol) was dripped and a white precipitate was obtained. Powdered potassium thiocyanate (26 g, 0.26 mol) was poured rapidly into the mixture and refluxed for 16 h and then allowed to cool. The solid was crushed, collected, and washed with water. The *o*-tolylthiourea was recrystallized from aqueous alcohol, yielded 30.4 g (78.3%), mp 155–156 °C (Lit. mp 155–156 °C [12]).

3.2. The preparation of the 2-amino-4-methylbenzothiazole 4

A solution of bromine (6.8 ml, 0.17 mol) in chloroform (50 ml) was poured into a mixture of the dry powdered *o*-tolylthiourea (20 g, 0.13 mol) and chloroform (60 ml) which was heated to boil contained in a 3-necked flask. Heat was evolved and the mixture rapidly gave a clear solution which was kept below 30 °C by external cooling. When the initial reaction had subsided the flask was fitted with a stirrer and condenser carrying a calcium chloride tube and the mixture refluxed until evolution of hydrogen bromide ceased (ca. 24 h), the hydrobromide of the 2-amino-4-methylbenzothiazole crystallizing out meanwhile. The mixture was set aside overnight. The cold mixture was filtered and the insoluble residue suspended in water and treated with sodium sulfite until traces of free bromine had been removed. The mixture was again filtered. The precipitate was collected, washed with water, and dried (average yield, 22.5 g, 76.2%) mp 253–254 °C (Lit. 254 °C [12]), ^1H NMR (DMSO- d_6) δ = 14.27 (s, 1H), 11.52 (s, 2H), 7.25–7.37 (m, 3H), 2.67 (s, 3H).

3.3. 2-Hydrazino-4-methylbenzothiazole 5

2-Amino-4-methylbenzothiazole (20 g, 0.82 mol) and hydrazine hydrate 85% (0.11 mol) in 50 ml of glycol refluxed (110–120 °C) while stirring for 4 h. The color of the reaction mixture changed to green, and gave a homogeneous solution. A white solid was precipitated at the end of the reflux period. The mixture was cooled and the product was filtered, washed with water, air-dried and recrystallized from ethanol to give white needles of 5. It gave 11 g (75.3%), mp 169–170 °C.

Table 7

Selected bond lengths (Å)

| | | | | | | | |
|-------|----------|-------|----------|--------|----------|--------|----------|
| S1C8 | 1.719(3) | N4C16 | 1.360(4) | C10C17 | 1.365(4) | C18C19 | 1.483(5) |
| S1C6 | 1.756(4) | C1C2 | 1.495(5) | C10C11 | 1.424(4) | C19C24 | 1.384(5) |
| N1C8 | 1.294(4) | C2C3 | 1.388(5) | C11C12 | 1.405(5) | C19C20 | 1.388(5) |
| N1N3 | 1.392(4) | C2C7 | 1.394(5) | C11C16 | 1.420(5) | C20C21 | 1.379(6) |
| N2C8 | 1.373(4) | C3C4 | 1.373(6) | C12C13 | 1.362(5) | C21C22 | 1.367(6) |
| N2C9 | 1.389(4) | C4C5 | 1.357(6) | C13C14 | 1.402(6) | C22C23 | 1.373(6) |
| N2C7 | 1.422(4) | C5C6 | 1.388(5) | C14C15 | 1.350(6) | C23C24 | 1.374(5) |
| N3C9 | 1.306(4) | C6C7 | 1.387(5) | C15C16 | 1.412(5) | | |
| N4C18 | 1.324(4) | C9C10 | 1.473(4) | C17C18 | 1.418(4) | | |

Table 8


Selected bond angles (°)

| | | | | | | | |
|----------|----------|-----------|----------|-----------|----------|-----------|----------|
| C8S1C6 | 88.7(2) | C5C6C7 | 121.9(3) | C17C10C9 | 119.3(3) | N4C18C17 | 121.8(3) |
| C8N1N3 | 105.1(3) | C5C6S1 | 123.4(3) | C11C10C9 | 120.7(3) | N4C18C19 | 117.4(3) |
| C8N2C9 | 103.4(2) | C7C6S1 | 114.6(2) | C12C11C10 | 124.3(3) | C17C18C19 | 120.6(3) |
| C8N2C7 | 113.7(3) | C6C7C2 | 121.1(3) | C12C11C16 | 119.3(3) | C24C19C20 | 117.9(3) |
| C9N2C7 | 142.9(3) | C6C7N2 | 109.1(3) | C10C11C16 | 116.4(3) | C24C19C18 | 122.0(3) |
| C9N3N1 | 109.6(3) | C2C7N2 | 129.8(3) | C13C12C11 | 120.6(4) | C20C19C18 | 119.9(3) |
| C18N4C16 | 118.8(3) | N1C8N2 | 112.9(3) | C12C13C14 | 120.0(4) | C21C20C19 | 120.5(4) |
| C3C2C7 | 115.7(3) | N1C8S1 | 133.3(3) | C15C14C13 | 121.0(4) | C22C21C20 | 120.7(4) |
| C3C2C1 | 119.1(3) | N2C8S1 | 113.8(2) | C14C15C16 | 120.7(4) | C21C22C23 | 119.3(4) |
| C7C2C1 | 125.3(3) | N3C9N2 | 108.9(3) | N4C16C15 | 118.3(3) | C22C23C24 | 120.3(4) |
| C4C3C2 | 122.5(4) | N3C9C10 | 120.2(3) | N4C16C11 | 123.3(3) | C23C24C19 | 121.1(4) |
| C5C4C3 | 122.1(4) | N2C9C10 | 130.7(3) | C15C16C11 | 118.4(3) | | |
| C4C5C6 | 116.7(4) | C17C10C11 | 119.5(3) | C10C17C18 | 120.1(3) | | |

^1H NMR (CDCl_3) δ = 6.93–7.57 (m, 3H), 4.96 (broad, 3H), 2.58 (s, 3H).

3.4. Novel 5-methyl-3-substituted-1,2,4-triazolo[3,4-b]benzothiazoles **6a–e**

A mixture of 2-hydrazino-4-methylbenzothiazole **5** (1 mmol), various aromatic carbonic acids (1 mmol) and POCl_3 (5 ml) was heated under reflux for 12 h. A portion of POCl_3 was distilled out and



Scheme 2.

the remaining reaction mixture poured into ice-water. The solution was basified by adding potassium hydroxide solution, the deposited solid was filtered off and recrystallized from ethanol to give the title 5-methyl-3-substituted-1,2,4-triazolo[3,4-b]benzothiazoles **6a–e**. The solid was separated by chromatographic column (silica gel, eluant ethyl acetate/petroleum ether 1:1). The results are given in Table 1.

The purified product was dissolved in ethyl acetate/petroleum ether/ethanol solution. The crystal was obtained after 7 days by evaporation of the solution.

Acknowledgements

The authors wish to acknowledge that this project is supported by University Key Teacher by the Ministry of Education, NNSFC(chuangxin qunti,2002-001), Gansu NSFC(ZS991-A25-003-Z) and Lanzhou University NLAOC.

References

- [1] A. Gvozdjakova, J. Habsudova, K. Kufcakov, *Stud. Org. Chem. (Amsterdam)* 38 (1988) 297 (Chem. Abstr. 1989, 110, 114741n).
- [2] D.S. Deshpande, *Acta Cienc. Indica (Ser.) Chem.* 6 (1980) 80.
- [3] R.K. Acngill, N. Matsuura, F. Tabuchi, *Eur. Pat.* 213 814, (1987), (Chem. Abstr. 1987, 107, 178600m).
- [4] Z.Y. Zhang, H.S. Dong, Y. Zhu, *Acta Chim. Sinica* 54 (1996) 1054.
- [5] Z.Y. Zhang, H.S. Dong, Z.W. Guan, S.Y. Yang, *Chem. Res. Chin. Univ.* 13 (1) (1997) 27.
- [6] Z.Y. Zhang, H.S. Dong, S.Y. Yang, *Org. Chem.* 16 (1996) 430.
- [7] Z.Y. Zhang, H.S. Dong, S.Y. Yang, *Org. Chem.* 18 (1998) 253.
- [8] B.S. Holla, A. D'Souza, B. Kalluraya, *J. Indian Chem. Soc.* 68 (1991) 250.
- [9] H.S. Dong, K. Wei, Q.L. Wang, B. Quan, Z.Y. Zhang, *J. Chin. Chem. Soc.* 47 (2000) 343.
- [10] H.S. Dong, K. Wei, Q.L. Wang, B. Quan, *J. Chin. Chem. Soc.* 47 (2000) 541.
- [11] M. Fehlmann, *Acta Cryst. B* 26 (1970) 1736.
- [12] C.E. Dalglish, F.G. Mann, *J. Am. Chem. Soc.* (1945) 893.